Evidence map›Paper›PMID 32488315›Full record

ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2020

Changes of lipoxin levels during pregnancy and the monthly-cycle, condition the normal course of pregnancy or pathology.

Małgorzata Szczuko, Joanna Palma, Justyna Kikut, Natalia Komorniak, Maciej Ziętek

Open access · hybridAbstract readReview
In one paragraph

Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. The great obstetrical syndromes and the placenta.BJOG : an international journal of obstetrics and gynaecology · 2023
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Could Lipoxins Represent a New Standard in Ischemic Stroke Treatment?International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Małgorzata SzczukoDepartment of Human Nutrition and Metabolomics, Pomeranian Medical University, Szczecin, Poland. malgorzata.szczuko@pum.edu.pl.ORCID http://orcid.org/0000-0001-9808-0624
Joanna PalmaDepartment of Human Nutrition and Metabolomics, Pomeranian Medical University, Szczecin, Poland.
Justyna KikutDepartment of Human Nutrition and Metabolomics, Pomeranian Medical University, Szczecin, Poland.
Natalia KomorniakDepartment of Human Nutrition and Metabolomics, Pomeranian Medical University, Szczecin, Poland.
Maciej ZiętekDepartment of Perinatology, Obstetrics and Gynecology, Pomeranian Medical University, Szczecin, Poland.
Pomeranian Medical University · PL

Funding

Ministerstwo Nauki i Szkolnictwa Wyższego 002 / RID / 2019/20
6 · The paper itself

Abstract

OBJECTIVE AND

designThe purpose of the review was to gather information on the role and possibilities of using lipoxin in the treatment of infertility and maintaining a normal pregnancy. Ovulation, menstruation, embryo implantation, and childbirth are reactions representing short-term inflammatory events involving lipoxin activities. Lipoxin A4 (LXA4) is an arachidonic acid metabolite, and in cooperation with its positional isomer lipoxin B4 (LXB4), it is a major lipoxin in mammals. Biosynthesis process occurs in two stages: in the first step, the donor cell releases the eicosanoid intermediate; secondarily, the acceptor cell gets and converts the intermediate product into LXA4 (leukocyte/platelet interaction).

resultsGenerating lipoxin synthesis may also be triggered by salicylic acid, which acetylates cyclooxygenase-2. Lipoxin A4 and its analogues are considered as specialized pro-resolving mediators. LXA4 is an important component for a proper menstrual cycle, embryo implantation, pregnancy, and delivery. Its level in the luteal phase is high, while in the follicular phase, it decreases, which coincides with an increase in estradiol concentration with which it competes for the receptor. LXA4 inhibits the progression of endometriosis. However, during the peri-implantation period, before pregnancy is confirmed clinically, high levels of LXA4 can contribute to early pregnancy loss and may cause miscarriage. After implantation, insufficient LXA4 levels contribute to incorrect maternal vessel remodeling; decreased, shallow trophoblastic invasion; and the immuno-energetic abnormality of the placenta, which negatively affects fetal growth and the maintenance of pregnancy. Moreover, the level of LXA4 increases in the final stages of pregnancy, allowing vessel remodeling and placental separation.

methodsThe review evaluates the literature published in the PubMed and Embase database up to 31 December 2019. The passwords were checked on terms: lipoxin and pregnancy with combined endometriosis, menstrual cycle, implantation, pre-eclampsia, fetal growth restriction, and preterm labor.

conclusionsAlthough no human studies have been performed so far, the cell and animal model study results suggest that LXA4 will be used in obstetrics and gynecology soon.

Indexed as

AnimalsEmbryo ImplantationEndometriosisFemaleFetal Growth RetardationHumansLipoxinsMenstruationObstetric Labor, PrematurePregnancylipoxin A4LipoxinsInflammationLipoxinMenstruationOvulationPregnancyReproduction

Identifiers

PMID32488315
PMCPMC7395003
OpenAlexW3029005028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.